Redefining the R1 resection for pancreatic ductal adenocarcinoma: tumour lymph nodal burden and lymph node ratio are the only prognostic factors associated with survival  by John, Biku J. et al.
ORIGINAL ARTICLE
Redefining the R1 resection for pancreatic ductal adenocarcinoma:
tumour lymph nodal burden and lymph node ratio are the only
prognostic factors associated with survival
Biku J. John1, Prashant Naik1, Alastair Ironside2, Brian R. Davidson1, Guiseppe Fusai1, Roopinder Gillmore3,
Jennifer Watkins2 & Sakhawat H. Rahman1
1Centre for HPB Surgery and Liver Transplantation, The Royal Free London NHS Foundation Trust, Departments of 2Histopathology, and 3Medical Oncology,
Royal Free Hospital, London, UK
Abstract
Introduction: The presence of positive nodal disease (LND) and the number of lymph nodes involved
(LNB) are known to be significant prognostic markers for resected adenocarcinoma of the pancreas. In
addition, the ratio of the number of involved nodes to the number of nodes resected known as the lymph
node ratio (LNR) is emerging as an important prognostic marker. The role of the resection margin (RM) as
presently defined (R1  1 mm) is unclear as results differ based on the dataset. The aim of this study was
to assess the impact of nodal disease and a redefined RM on outcome.
Material and methods: Retrospective analysis of pancreatic head resections for adenocarcinomas
from 2003–2009. The RM was re-analysed based on tumour clearance and categorized into: histopatho-
logical evidence of a tumour; 0.5 mm, 1 mm, 1.5 mm, or 2.0 mm of the actual surgical resection
margin. The impact of histopathological variables on cancer-specific survival (CSS) and disease-free
survival (DFS) was analysed.
Results: LND, LNB and LNR were independent prognostic markers for CSS (P = 0.048, 0.003, 0.016)
but, did not influence DFS. A LNR < 0.143 was associated with a higher CSS [38.16  4.69 versus 20.59
 2.20 months, P = 0.0042, hazard ratio (HR) 3.74 (95% confidence interval (CI) 1.52–9.23)]. An R1 RM
was not associated with CSS or DFS on multivariate analysis, irrespective of the distance. LNB and LNR
maintained independent significance irrespective of the size of the RM.
Conclusion: LNB and LNR are the only prognostic factors for CSS in patients with pancreatic head
adenocarcinoma, but do not predict recurrence. Microscopic RMs does not seem to influence the
outcome even when redefined. Further prospective studies are indicated to substantiate these findings.
Received 3 June 2012; accepted 26 September 2012
Correspondence
Sakhawat H. Rahman, Consultant Pancreatic and Minimally Invasive Surgery, Royal Free Hospital, Pond
Street, London, NW3 2QG, UK. Tel: +44 2077940500. Fax: +44 2078302688. E-mail: zak.rahman@nhs.net
Introduction
The long-term prognosis for patients with pancreatic cancer
remains dismal with 5-year survival ranging from 15–25%.1–4 A
surgical resection offers the best chance for a cure and remains the
mainstay of therapy. However, only 10–20% of patients present
with resectable disease.5,6 Adjuvant chemotherapy has been shown
to almost double the 5-year survival after a successful resection.7,8
The failure to significantly influence outcome in pancreatic cancer
in contrast to other site cancers reflects a lack of understanding of
pancreatic tumour biology.
Numerous studies have evaluated histological parameters that
predict outcome after surgery.3,4,9,10 While lymph node positivity,
tumour stage and grade, microscopic resection margins, lym-
phovascular and perineural invasion and tumour size have all
been associated with a poor outcome, results vary based on the
dataset.3,4,9–11 Lymph nodal metastases is probably the most con-
sistent factor associated with poor outcome although the exact
nature of its association is as yet unclear. Three patterns of this
association have been identified: (i) the presence of 1 involved
nodes (LND, lymph node disease); (ii) an increasing number of
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nodes infiltrated by the tumour (LNB, lymph node burden); and
(iii) an increasing ratio of the positive to examined nodes (lymph
node ratio, LNR).1,3,12 The association between lymph nodal
metastases and local disease recurrence/disease-free survival
(DFS) has not been previously reported.
Although there is little doubt that an incomplete resection por-
tents poor outcome, the significance of the negative resection
margin is unclear. Currently, a resection margin >1 mm is consid-
ered negative.13 Unlike the data supporting the importance of a
1-mm circumferential resection margin (CRM) in rectal can-
cers,14,15 robust scientific evidence is lacking in pancreatic cancers.
Further, the significance of a R0 resection in predicting outcome
has been variable depending on the dataset analysed.3,16–24 It is
likely that these outcomes may be influenced by the definition of
R0, which may in itself be intrinsically flawed or, may be variably
influenced by specific margins in relation to the tumour or, by the
size of the study.
The aim of this study was to determine the histopathological
variables that influenced the outcome with particular emphasis on
the lymph node status and the resection margins (RM). The
current definition of an R0 resection was redefined and the influ-
ence of specific margin status on DFS and overall survival (OS)
was assessed.
Material and methods
Retrospective analysis of prospectively collected data on all
patients undergoing a potentially curative pancreaticoduodenec-
tomy for pancreatic ductal adenocarcinoma at the Royal Free
hospital, London, UK, from 2003–2009. Data collected included
demographic variables, details of surgery, time to recurrence or
date of latest clinical review, time to death or latest clinical review
and the use of adjuvant therapy.
The pancreaticoduodenectomy specimens were all dissected
according to The Royal College of Pathologists (RCP) guidelines.13
Margins were inked prior to sectioning with different colours for
each margin and the specimen sliced in the axial plane. Six differ-
ent resection margins were measured microscopically and
recorded, namely proximal duodenal (or gastric), distal duodenal,
pancreatic, common bile duct, posterior and superior mesenteric
(SMV)/ portal vein (PV) groove. A margin of >1 mm was
reported as negative (R0). Distance from the tumour to the ante-
rior surface was also noted. Other data included the type, grade
and size of the cancer, the total number of nodes within the
resected specimen and the total number of nodes involved with
cancer. Lymph nodal disease (LND) was defined as the presence of
1 metastatic nodes, lymph nodal burden (LNB) was the number
of nodes infiltrated by a tumour and the lymph nodal ratio (LNR)
was the ratio of metastatic nodes to total nodes examined.
All the available histopathological specimens were re-examined
by independent pathologists (J.W. and A.I.) to accurately define
the R0 status based on tumour clearance and to re-categorize
the R1 status based on histopathological evidence of a tumour
0.5 mm, 1 mm, 1.5 mm or 2.0 mm of the actual surgical
resection margin (re-defined status).
All clinicopathological variables were correlated with cancer-
specific survival (CSS) and DFS. DFS was based on the diagnosis
of local or systemic recurrence identified through a combination
of radiological imaging, tumour marker levels and biopsy. Local
disease recurrence was confirmed either by biopsy and or the
progression of lesions on subsequent follow-up scans. All patients
underwent 3-monthly CT scans (chest, abdomen and pelvis) and
serum tumour marker (CEA and CA19-9) analysis for at least 2
years after a surgical resection. Hence, all patients that were oper-
ated locally but followed up at other centres were excluded to
ensure accuracy.
Specific exclusions included patients with adenocarcinoma
arising in the background of an intraductal papillary mucinous
neoplasm (IPMN), non-cancerous pathology, patients who
underwent a total pancreatectomy, patients who died in the peri-
operative period or within 30 days of discharge and deaths unre-
lated to tumour recurrence.
Statistical analysis
All the analysis was done using STATVIEW (SAS Institute Inc.,
Cary, NC, USA). Descriptive statistics was used to present demo-
graphic and treatment-related data. OS and DFS were univarietly
analysed using the Kaplan–Meier method. The log-rank test was
used to compare subgroups. Factors found to be associated with
P  0.1 on univariate analysis were included in the multivariate
analysis. Cox’s proportional hazard was used for multivariate
analysis. Statistical significance was set at P  0.05. Lymph nodal
data were analysed as both nominal and continuous variables.
Results
A total of 86 patients identified from the pathological specimen
database had undergone a laparotomy for resection of a pancre-
atic head adenocarcinoma from 2003–2009. Of these, 70 fulfilled
all the criteria to be included in the study. Sixteen (19%) patients
were excluded: six distal cholangiocarcinomas (incorrect coding),
three total pancreatectomies, four periampullary tumours, one
peri-operative death and two adenocarcinoma with background
IPMN. The clinicopathological characteristics of the cohort
and the operation performed are listed in Table 1. The median
follow-up period was 19.5 months (range 2.5–101.3). 24/70
(34.3%) were alive at the time of inclusion.
Survival
CSS data were available in all 70 patients. The mean time to death
was 22.90  17.40 months (range: 3–101.13). On univariate
analysis, the degree of differentiation (P = 0.031), lymphovascular
invasion (P = 0.013), LND (presence of 1 positive nodes,
P = 0.005) significantly affected CSS. (Table 2, Fig. 1) LNB
(P = 0.0005), total nodes examined (P = 0.034) and the LNR (P =
0.018) were significantly associated with CSS when analysed as
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continuous variables. On multivariate analysis only the LNB, LNR
and LND maintained significance (P = 0.0029, 0.016 and 0.048,
respectively) (Table 2).
DFS was determined in 34 patients in whom all data were
available. The mean time to recurrence was 9.89  7.54 months
(range: 1.27–58.35). On univariate analysis, lymphovascular inva-
sion (P = 0.022) and positive lymph node status (P = 0.016)
significantly affected DFS (Table 2).
Receiver-operator curve (ROC) analysis was used to determine
the association between the LNR and CSS based on mortality
during the study period. The best cut-off for LNR with regards to
survival was determined at 0.143 (area under curve = 0.730).
Patients with a LNR < 0.143 had a significantly higher survival
than those with a higher LNR both on univariate and multivariate
analyses [38.16  4.69 versus 20.59  2.20 months, P = 0.0042,
hazard ratio (HR) 3.74 (95% CI 1.52–9.23)] (Fig. 1). There was no
significant difference in the total number of examined nodes
between these two groups (P = 0.81).
RM status and survival
The overall R0 resection rate based on the RCP guidelines was
25.7%, and was significantly associated with OS (P = 0.015) on
univariate but not on multivariate analysis (P = 0.84). No associa-
tion was found with DFS. The SMV/PV groove margin was the
most common resection margin involvement (Table 1). A signifi-
cant correlation was found between lymph node and margin
positivity [P = 0.01, OR4.50 (95% CI 1.3–15.70)]. However, sub-
grouping patients into node negative and node positive groups
did not reveal any significant correlation between resection
margin status and CSS (Table 5).
Redefining the RM status demonstrated a significant associa-
tion with OS for completeness of resection (R0), and for the
specific margins involving the PV/SMV groove and posterior
resection margin for all groups (0.5, 1, 1.5 and 2 mm) (Table 3).
However, these were not maintained on multivariate analysis.
Multivariate regression analysis confirmed that the LNR and
LNB maintained their independent influence on CSS irrespective
of the chosen cut-off for what was considered to be completeness
of resection in all groups, whereas lymph nodal status maintained
significance only for a RM status 1 and 1.5 mm (Table 4).
Discussion
This study reaffirms the adverse prognostic effect of lymph nodal
metastases on survival after a pancreatic head resection for ductal
adenocarcinoma. This study has shown that LND, LNB and LNR
independently influence outcome. However, these findings are not
entirely consistent with previous studies and opinion is still
guarded as to the exact nature of the relationship between lymph
nodal metastases and outcome.1,3,12
A number of retrospective studies have analysed the relation-
ship between survival and extent of lymph node assessment after
resection of pancreatic tumours.1,12,25 An inadequate surgical
lymphadenectomy or pathological assessment would understage
patients owing to the potential of missing metastatic nodes. A
large review of 1666 patients within the Surveillance, Epidemiol-
ogy and End results (SEER) database for pancreatic cancer sug-
gested that an attempt to harvest and resect at least 15 lymph
nodes was essential for accurate staging.26 Higher nodal yields
were not associated with significant survival differences at any
stage.26 Similarly, a study by the Memorial Sloan–Kettering Cancer
Centre group showed that a lymph node harvest of 12 nodes
provided accurate survival estimates in patients with node nega-
tive disease.1 The median nodes examined in this study was 14
(IQR 8) and, unlike the SEER database study, there was no signifi-
cant difference in the total number of nodes examined between
the nodes positive and nodes negative group [median 15.0 (range:
3–49) versus 10.0 (range: 4–25); P = 0.140].
It has been suggested that the use of LND alone or LNB may
carry the bias of an inadequate lymphadenectomy or histopatho-
logical examination. Previous studies in both colorectal and
gastric cancer have shown that a ratio-based classification of
lymph nodes was far superior to LNB and LND in predicting
survival.27–29 The same seems to be true for pancreatic tumours
where the LNR is emerging as the candidate marker for prognosis
as opposed to the LND or LNB.1,12,25 These data showed that a
LNR 0.143 was associated with reduced survival [HR 3.74 (95%
Table 1 Demographic, operative and histopathological variables
Variable Value
Median age in years (interquartile range) 65.79 (16.77)
Gender Male 35; female 35
Operation PPPD 60 (85.70%)
Whipples 10 (14.30%)
Vascular resection 11 (15.70%)
Max. tumour size in mm – median
(interquartile range)
30.00 (16)
Differentiation Well 7 (10%)
Moderate 37 (52.90%)
Poor 26 (37.14%)
Surgical margins R0/R1 R0–18 (25.7%);
R1–52 (74.3%)
Anterior +ve 21 (30%)
Posterior +ve 32 (45.70%)
SMV/PV groove +ve 33 (47.10%)
CBD +ve 2 (2.9%)
Pancreatic edge +ve 2 (2.9%)
Perineural invasion +ve 65 (92.90%)
Lymphovascular invasion +ve 38 (54.30%)
Nodal status Nodal status +ve 55 (78.60%)
Median nodes examined 14 (IQR 8)
Median +ve nodes examined 2.0 (IQR 3)
PPPD, pylorus-preserving pancreaticoduodenectomy; SMV/PV, superior
mesenteric/portal vein; CBD, common bile duct.
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CI 1.52–9.23)]. Unlike this study, an association between LNB and
LND has not been a consistent finding in previous studies, and
this disparity can be explained as a result of a number of clinical
and pathological differences in the datasets.1,3,4,9,10,12 As it stands,
LNR appears to be the most consistent marker for stratification of
prognosis.
The majority of reported series have included tumours not
confined to the head of the pancreas, tumours other than ductal
adenocarcinomas, and above all there appears to be a huge differ-
ence in the reporting of a resection margin status suggesting
inconsistent reporting of histopathological specimens.1,12,16,25,30–32
The large population-based study by Slidell et al. included histo-
logical variants such as adenosquamous and signet ring cell car-
cinomas; the biology of these are likely to differ influencing the
outcome.32 Numerous other studies reporting on lymph nodes
included resections for tumours in the head, body and tail, requir-
ing anatomically varied resections. Their patterns of spread are
different, as are their outcomes.1,12,25,29 Such confounding variables
have been eliminated in this dataset. Unlike previous studies, this
dataset included a homogenous population of patients with
primary adenocarcinoma of the head of the pancreas who have
undergone a pancreaticoduodenectomy alone.
Table 2 Impact of demographic, surgical and histopathological variables on survival
Variables Overall survival Disease-free survival
Median OS
(IQR) – mths
Univariate
P-value
Multivariate
P-value
Median OS
(IQR) – months
Univariate
P-value
Multivariate
P-value
Gender 0.618 0.819
Vascular resection 0.674 0.678
Type of reconstruction 0.754 0.844
Tumour size 0.13 0.955
Differentiation (Binomial Variable) Well/Mod 18.57 (16.65) 0.031 0.161 7.42 (6.37) 0.06 0.30
Poorly 13.53 (19.68) 6.08 (6.08)
Neural invasion 0.973 0.631
Lymphovascular invasion -ve 24.26 (26.56) 0.013 0.631 8.3 (13.1) 0.022 0.155
+ve 16.37 (15.65) 7.42 (7.0)
SMV/PV groove invasion -ve 19.57 (27.98) 0.065 0.167 0.363
+ve 14.47 (18.84)
Resection status (R0/R1) -ve 22.43 (28.53) 0.015 0.840 0.301
+ve 16.30 (18.48)
Ant. margin status 0.275 0.838
Post. margin status -ve 18.57 (22.58) 0.062 0.652 0.012 0.292
+ve 16.30 (17.78)
CBD margin 0.762 0.507
+ve lymph node status -ve 26.13 (32.26) 0.005 0.048 10.34 (17.52) 0.016 0.075
+ve 16.30 (16.27) 7.10 (6.80)
Lymph node ratio (LNR)* 0.018 0.016 0.287
Lymph node burden (LNB)* 0.0005 0.0029 0.207
Total nodes* 0.034 0.106 0.444
CBD, common bile duct; LNR, lymph node ratio; LNB, lymph node burden.
Figure 1 Influence of the lymph node ratio (LNR) stratification on
overall survival (OS) – Kaplan–Meier survival curves and the numbers
at the risk table
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A recent study by Murikami et al. factored in the role of adju-
vant chemotherapy and showed that LNB and lymph node posi-
tivity status predicted outcome, but not LNR.33 A key contributor
to their observations may have been the fact that an extended
lymphadenectomy was performed in the vast majority of their
patient cohort (mean number of nodes examined was 29),
perhaps allowing a better nodal staging of the disease. As the
chemotherapy practice was variable, we could not include data in
our analysis. Randomized controlled trials have confirmed the
positive effect of chemotherapy on survival and is likely to influ-
ence the results.8,19
This study also shows that lymph nodal metastasis is not a
marker for early recurrence as evidenced by the lack of an asso-
ciation between LND, LNB and LNR, and DFS. This finding
assumes significance as most previous studies reporting on the
prognostic significance of lymph nodes take into account the CSS
but not DFS. As routine surveillance does not improve outcome
even if metastases are detected early, estimation of DFS is often
inaccurate. Owing to our surveillance policy of 3 monthly CT
scanning even in patients not receiving adjuvant therapy, we could
determine DFS. However, the numbers were significantly smaller
than those analysed for CSS owing to our referral practice. This
lack of an association between lymph nodal status and DFS sug-
gests that patients with lymph node metastases do not recur
earlier than those without, but once recurrence occurs they
succumb faster. This could result from differences in tumour
biology, differential sites of metastases or possibly the tendency of
these tumours to de-differentiate as recurrence manifests. It
would be interesting to compare the sites of recurrence in these
groups of patients. We acknowledge the limitations of our study in
that the dataset for the DFS group is significantly smaller than the
CSS group and hence, the possibility of a type2 error.
Previous studies have shown a variable effect of the RM on
survival. Differences in pathological reporting, surgical tech-
nique, definition of positivity and group stratification affects
outcome analyses.34 Additionally, margin positivity has not been
shown to be significant on multivariate analysis in a number of
studies.34 Campbell et al. reviewed the histology of 128 patients
undergoing a pancreatic resection for adenocarcinoma reported
Table 3 Impact of varying the resection margin (RM) status on cancer-specific survival (CSS) and disease-free survival (DFS) (re-reported
specimens)
Margin value (mm) Margin site OS DFS
Univariate
P-value
Multivariate
P-value
Univariate
P-value
Multivariate
P-value
0.5 Ant. margin 0.708 0.837
Post. margin 0.196 0.097 0.683
SMV groove 0.051 0.130 0.156
R0/R1 0.064 0.846 0.670
1.0 Ant. margin 0.275 0.838
Post. margin 0.062 0.652 0.012 0.292
SMV groove 0.065 0.167 0.363
R0/R1 0.015 0.840 0.301
1.5 Ant. margin 0.163 0.461
Post. margin 0.087 0.486 0.066 0.963
SMV groove 0.062 0.115 0.536
R0/R1 0.016 0.810 0.267
2.0 Ant. margin 0.179 0.575
Post. margin 0.11 0.106
SMV groove 0.031 0.093 0.544
R0/R1 0.007 0.54 0.262
OS, overall survival.
Table 4 Influence of the redefined resection margin status on the
association between lymph nodal positivity (LNP), lymph node
burden (LNB), lymph node ratio (LNR) and cancer-specific Survival
(CSS)
Resection
margin (R0
defined
as under)
LNP
Multivariate
P-value
LNB
Multivariate
P-value
LNR
Multivariate
P-value
0.5 0.105 0.007 0.032
1.0 0.048 0.0029 0.016
1.5 0.041 0.003 0.010
2.0 0.156 0.004 0.018
The redefined resection margins significantly impacts CSS on univariate
analyses (Table 3). This along with other significant factors (Table 2) has
been incorporated in the multivariate model to assess whether the
Lymph node status retains significance irrespective of the redefined
margins.
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as having an R1 resection.35 Of these, 57 (45%) were based on
equivocal margins (tumour involvement within 1 mm of, but not
directly reaching, one or more resection margins). There was no
difference in survival between the equivocal and unequivocal
groups. All R1 resections had a poorer survival as compared with
R0 resections on univariate but not on multivariate analysis.
Menon et al. demonstrated that R1 resections adversely affected
survival on univariate analysis alone.36 R0 resection rates of
15–30% is noted in centres that use the RCP guidelines for
pathological reporting; the rate in this study is 25.7%.36,37 In con-
trast, the reported R0 resection rates from the US are much
higher (55–85%) suggesting a difference in pathological staging
standards.1,12,25,31 In spite of these differences in pathological
reporting, RM status was not associated with survival on multi-
variate analyses in any of these studies. This would suggest that
the RM is not a significant prognostic factor for survival. Inter-
estingly in our dataset, there is a significant correlation between
lymph node and margin positivity (P = 0.001). Further 78% of
this dataset had positive lymph node disease. This could suggest
that lymph node positivity has a stronger influence on outcome
as compared with RM status. When the RM in node negative
patients alone was examined no significance was found in the
outcome between R0 and R1 resections on univariate analysis
(Table 5). However, the numbers were too small for any mean-
ingful interpretation of and the chance of a type2 error is highly
likely.
Redefining the resection margin did not impact the prognostic
significance on multivariate analysis. Incorporating the margin
status into a multivariate analysis showed that the LNR and LNB
maintained their significance throughout all margin sizes, whereas
the lymph nodal positivity status was variable depending upon the
margin cutoff. This suggests that the LNR and LNB are better
prognostic indicators than the RM.4
Conclusion
This study is the first report to demonstrate a clear and independ-
ent association of tumour lymph node burden and the LNR with
OS irrespective of the resection margin status as it stands currently
or, if redefined. The presence of LND did not seem to affect DFS.
However, the small size of the study and the lack of chemotherapy
data might significantly influence the results. Hence, large
controlled prospective studies to define the exact relationship
between lymph nodes and RM, and outcome are indicated.
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